CVS Group plc has responded to the Competition and Markets Authority's (CMA) decision to initiate a market investigation reference regarding the supply of veterinary services for household pets in the UK. The company has expressed its commitment to proactively support the CMA throughout the investigation, emphasizing its dedication to providing the best possible care to animals and its vision to be the veterinary company people most want to work for.
In November 2023, CVS launched a new clinical governance framework, which places contextualized care at the heart of its approach to providing clients and their pets with appropriate care. The company's focus on understanding client needs is encapsulated in the mantra "what matters to you, matters to us."
The market investigation is set to be conducted over the next 18 months, and CVS looks forward to further updates from the CMA at the appropriate time. The company operates approximately 460 veterinary practices across the UK and Australia, including specialist referral hospitals, dedicated out-of-hours sites, laboratories, crematoria, and an online retail business.
CVS Group plc's leadership, including CEO Richard Fairman, Deputy CEO Ben Jacklin, and CFO Robin Alfonso, have been listed as contacts for further information. The company's Nominated Adviser & Joint Broker is Peel Hunt LLP, and its Joint Broker is Berenberg. Camarco serves as CVS Group's Financial PR.
For more information about CVS Group plc, visit their website at www.cvsukltd.co.uk.